|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0018067,
umls-concept:C0021359,
umls-concept:C0086582,
umls-concept:C0231335,
umls-concept:C0332167,
umls-concept:C0332293,
umls-concept:C0443252,
umls-concept:C0444956,
umls-concept:C1261473,
umls-concept:C1883709
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
Therapy with alkylating agents, such as cyclophosphamide, can be associated with irreversible gonadal toxicity in male survivors of adult cancer. To the authors's knowledge the effect of high dose therapy with cyclophosphamide during childhood on adult testicular reproductive and endocrine function has not been established.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
613-21
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11169946-Adolescent,
pubmed-meshheading:11169946-Adult,
pubmed-meshheading:11169946-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11169946-Child,
pubmed-meshheading:11169946-Child, Preschool,
pubmed-meshheading:11169946-Cyclophosphamide,
pubmed-meshheading:11169946-Follicle Stimulating Hormone,
pubmed-meshheading:11169946-Genitalia, Male,
pubmed-meshheading:11169946-Humans,
pubmed-meshheading:11169946-Infertility, Male,
pubmed-meshheading:11169946-Luteinizing Hormone,
pubmed-meshheading:11169946-Male,
pubmed-meshheading:11169946-Risk Factors,
pubmed-meshheading:11169946-Sarcoma,
pubmed-meshheading:11169946-Testosterone
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood.
|
|
pubmed:affiliation |
Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. lisa_kenney@DFCI.harvard.edu
|
|
pubmed:publicationType |
Journal Article
|
